Pacific Biosciences of California, Inc. (PACB)
Automate Your Wheel Strategy on PACB
With Tiblio's Option Bot, you can configure your own wheel strategy including PACB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PACB
- Rev/Share 0.5138
- Book/Share 0.12
- PB 19.2143
- Debt/Equity 19.3982
- CurrentRatio 6.237
- ROIC -0.8629
- MktCap 695896628.0
- FreeCF/Share -0.4197
- PFCF -5.5116
- PE -1.3769
- Debt/Assets 0.8717
- DivYield 0
- ROE -2.8952
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler's 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY.
Read More
Top 3 Genomics Stocks to Consider for Your Portfolio
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Read More
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Negative
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
Read More
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics
Read More
Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Read More
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.
Read More
PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project
Published: October 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine
Read More
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.
Read More
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
Read More
Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date
Read More
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
Published: October 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing
Read More
PacBio Enters Carrier Screening Market With PureTarget Expansion
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
Read More
PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening
Read More
Pacific Biosciences Of California, Inc. (PACB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Christian Henry - President, CEO & Director Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics team here at Morgan Stanley.
Read More
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
Published: September 05, 2025 by: Zacks Investment Research
Sentiment: Positive
PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.
Read More
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer
Read More
Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.
Read More
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
Read More
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools
Read More
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.
Read More
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Read More
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Read More
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif. , June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date.
Read More
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
PacBio Stock Slips Despite New China Distribution Deal With Haorui
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
Read More
PACB Stock May Rise Following the Deal With Chulalongkorn University
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
Read More
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K.
Read More
About Pacific Biosciences of California, Inc. (PACB)
- IPO Date 2010-10-27
- Website https://www.pacb.com
- Industry Medical - Devices
- CEO Christian O. Henry
- Employees 575